NL301106I2 - Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan - Google Patents
Cenobamaat of een farmaceutisch aanvaardbaar zout daarvanInfo
- Publication number
- NL301106I2 NL301106I2 NL301106C NL301106C NL301106I2 NL 301106 I2 NL301106 I2 NL 301106I2 NL 301106 C NL301106 C NL 301106C NL 301106 C NL301106 C NL 301106C NL 301106 I2 NL301106 I2 NL 301106I2
- Authority
- NL
- Netherlands
- Prior art keywords
- cenobamate
- pharmaceutically acceptable
- acceptable salt
- salt
- pharmaceutically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67453005P | 2005-04-22 | 2005-04-22 | |
PCT/KR2006/001523 WO2006112685A1 (en) | 2005-04-22 | 2006-04-21 | Neurotherapeutic azole compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
NL301106I1 NL301106I1 (nl) | 2021-06-02 |
NL301106I2 true NL301106I2 (nl) | 2021-08-03 |
Family
ID=37115369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL301106C NL301106I2 (nl) | 2005-04-22 | 2021-05-31 | Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan |
Country Status (21)
Country | Link |
---|---|
US (1) | US7598279B2 (nl) |
EP (1) | EP1879873B1 (nl) |
JP (1) | JP5035238B2 (nl) |
KR (1) | KR101286499B1 (nl) |
CN (1) | CN101228138B (nl) |
AR (1) | AR053065A1 (nl) |
AU (1) | AU2006237798B2 (nl) |
BR (1) | BRPI0607529B8 (nl) |
CA (1) | CA2606258C (nl) |
DK (1) | DK1879873T3 (nl) |
ES (1) | ES2441765T3 (nl) |
FI (1) | FIC20210018I1 (nl) |
MX (1) | MX2007013197A (nl) |
MY (1) | MY148589A (nl) |
NL (1) | NL301106I2 (nl) |
PL (1) | PL1879873T3 (nl) |
PT (1) | PT1879873E (nl) |
RU (1) | RU2418792C2 (nl) |
TW (1) | TWI398249B (nl) |
WO (1) | WO2006112685A1 (nl) |
ZA (1) | ZA200709994B (nl) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
ES2379848T3 (es) * | 2007-05-14 | 2012-05-04 | Sk Biopharmaceuticals Co., Ltd. | Compuesto arilpiperazina arilalcanoil carbomoiloxi novedoso, composiciones farmacéuticas que comprenden el compuesto y método para tratar el dolor, ansiedad y depresión al administrar el compuesto |
NZ581364A (en) | 2007-06-05 | 2011-10-28 | Nsab Af Neurosearch Sweden Ab | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
WO2009148290A2 (en) * | 2008-06-05 | 2009-12-10 | Sk Holdings Co., Ltd. | 3-substituted propanamine compounds |
AU2009348523B2 (en) * | 2009-06-22 | 2015-02-26 | Sk Biopharmaceuticals Co., Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
KR101783632B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 주의력 결핍/과잉행동 장애(adhd)의 치료 방법 |
WO2011055944A2 (en) | 2009-11-06 | 2011-05-12 | Sk Holdings Co., Ltd. | Methods for treating fibromyalgia syndrome |
US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
NZ626973A (en) * | 2012-01-06 | 2016-09-30 | Novartis Ag | Heterocyclic compounds and methods for their use |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
TWI698415B (zh) * | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
WO2018111003A1 (ko) | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
CA3046458A1 (en) * | 2016-12-14 | 2018-06-21 | Sk Biopharmaceuticals Co., Ltd. | Parenteral liquid preparation comprising carbamate compound |
KR102635936B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
US11033531B2 (en) * | 2016-12-14 | 2021-06-15 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome |
IL267195B2 (en) | 2016-12-14 | 2024-05-01 | Sk Biopharmaceuticals Co Ltd | Use of carbamate compounds to prevent, alleviate, or treat bipolar disorder |
JP7090616B2 (ja) * | 2016-12-14 | 2022-06-24 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物を含む口腔内崩壊錠 |
CA3081224A1 (en) * | 2017-11-14 | 2019-05-23 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for reducing or treating developmental disorders including fragile x syndrome, angelman syndrome or rett syndrome |
KR20200074155A (ko) | 2017-11-14 | 2020-06-24 | 에스케이바이오팜 주식회사 | 근긴장증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
PL3711758T3 (pl) * | 2017-11-14 | 2024-07-01 | Sk Biopharmaceuticals Co., Ltd. | Zastosowanie związku karbaminianowego do zapobiegania, łagodzenia lub leczenia napadów nieświadomości lub padaczki wykazującej napady nieświadomości |
CA3081226A1 (en) | 2017-11-14 | 2019-05-23 | Sk Biopharmaceuticals Co., Ltd. | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
KR20200074156A (ko) * | 2017-11-14 | 2020-06-24 | 에스케이바이오팜 주식회사 | 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도 |
KR102739580B1 (ko) * | 2017-11-14 | 2024-12-06 | 에스케이바이오팜 주식회사 | 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
KR20210047888A (ko) | 2018-09-21 | 2021-04-30 | 에스케이바이오팜 주식회사 | 카바메이트 화합물 및 이를 포함하는 배합물의 급성 스트레스 장애 또는 외상 후 스트레스 장애의 예방, 경감 또는 치료를 위한 용도 |
WO2020060252A1 (ko) | 2018-09-21 | 2020-03-26 | 에스케이바이오팜 주식회사 | 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도 |
EP3868375A4 (en) | 2018-10-19 | 2022-06-29 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy |
US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
AU2020389425A1 (en) * | 2019-11-22 | 2022-06-02 | Sk Biopharmaceuticals Co., Ltd. | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor |
CN116322641A (zh) * | 2020-08-06 | 2023-06-23 | 爱思开生物制药株式会社 | 包含氨基甲酸酯化合物的固体口服组合物及其制备方法 |
CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
CN115716810A (zh) * | 2022-11-15 | 2023-02-28 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3415840A (en) * | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
DK181988A (da) * | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
ES2294140T3 (es) * | 2001-06-25 | 2008-04-01 | Sk Holdings Co Ltd. | Carbamatos de 2-heterociclico-1,2-etanodioles. |
US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh active Active
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en active Application Filing
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es active Active
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en active Active
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko active IP Right Grant
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en active Active
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja active Active
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 CA CA2606258A patent/CA2606258C/en active Active
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0607529B8 (pt) | 2021-05-25 |
BRPI0607529A2 (pt) | 2009-09-15 |
AR053065A1 (es) | 2007-04-18 |
TW200722085A (en) | 2007-06-16 |
KR20080005437A (ko) | 2008-01-11 |
DK1879873T3 (da) | 2013-12-09 |
AU2006237798B2 (en) | 2012-07-12 |
ZA200709994B (en) | 2008-11-26 |
US7598279B2 (en) | 2009-10-06 |
ES2441765T3 (es) | 2014-02-06 |
MX2007013197A (es) | 2008-02-12 |
WO2006112685A1 (en) | 2006-10-26 |
NL301106I1 (nl) | 2021-06-02 |
EP1879873B1 (en) | 2013-10-09 |
US20060258718A1 (en) | 2006-11-16 |
EP1879873A4 (en) | 2011-06-15 |
KR101286499B1 (ko) | 2013-07-16 |
PL1879873T3 (pl) | 2014-03-31 |
CA2606258A1 (en) | 2006-10-26 |
BRPI0607529B1 (pt) | 2021-05-18 |
RU2418792C2 (ru) | 2011-05-20 |
PT1879873E (pt) | 2014-01-03 |
CN101228138B (zh) | 2012-11-21 |
JP5035238B2 (ja) | 2012-09-26 |
TWI398249B (zh) | 2013-06-11 |
RU2007143073A (ru) | 2009-05-27 |
CA2606258C (en) | 2014-01-14 |
FIC20210018I1 (fi) | 2021-06-14 |
AU2006237798A1 (en) | 2006-10-26 |
CN101228138A (zh) | 2008-07-23 |
JP2008538557A (ja) | 2008-10-30 |
MY148589A (en) | 2013-05-15 |
EP1879873A1 (en) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301106I1 (nl) | Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan | |
NL301209I1 (nl) | capmatinib of een farmaceutisch aanvaardbaar zout daarvan | |
NL301003I2 (nl) | Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan | |
NL300993I2 (nl) | Apalutamide of een farmaceutisch aanvaardbaar zout daarvan | |
NL350108I2 (nl) | Isofetamid of een zout daarvan | |
NL301256I2 (nl) | cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan | |
NL300865I1 (nl) | Eluxadoline of een farmaceutisch aanvaardbaar zout ervan | |
NL301202I1 (nl) | Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline | |
NL301305I2 (nl) | Vibegron of een farmaceutisch aanvaardbaar zout daarvan | |
NL301177I1 (nl) | tecovirimat of een farmaceutisch aanvaardbaar zout daarvan | |
NL301166I2 (nl) | Avacopan of een farmaceutisch aanvaardbaar zout daarvan | |
NL301071I2 (nl) | alpelisib of een farmaceutisch aanvaardbaar zout ervan | |
NO2024010I1 (no) | Gefapixant, or a pharmaceutically acceptable salt thereof | |
NL301150I2 (nl) | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
NL301037I2 (nl) | Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan | |
NL301049I1 (nl) | Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
NL301304I2 (nl) | aprocitentan of een farmaceutisch aanvaardbaar zout daarvan | |
NL301158I2 (nl) | Relugolix of een zout daarvan | |
NL301042I1 (nl) | Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
NL301250I2 (nl) | piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan | |
FIC20240039I1 (fi) | Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa | |
NO2019027I1 (no) | kobicistat eller et farmasøytisk akseptabelt salt derav | |
FIC20210017I1 (fi) | Kabotegraviiri tai sen farmaseuttisesti hyväksyttävä suola tai solvaatti | |
NO2020038I1 (no) | Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt | |
NL300640I2 (nl) | Alogliptine of een farmaceutisch aanvaardbaar zout daarvan |